FLT3-IN-43

FLT3-IN-43 (compound 6h) (15-25 nM; 72 h) exhibits nanomolar antiproliferative potency against HCT116, A549, and MDA-MB-231 human solid tumor cell lines, with IC₅₀ values ranging from 15 nM to 25 nM^[1].
FLT3-IN-43 (72 h) exhibits exceptionally potent antiproliferative activity against FLT3-driven leukemia cell lines, with no observable toxicity to normal human PBMC at concentrations up to 10 μM^[1].
FLT3-IN-43 potently inhibits in vitro tubulin polymerization with an IC₅₀ of 3.6 μM^[1].
FLT3-IN-43 (1-10 μM; 2 h, 1.5 h) specifically occupies the colchicine binding site on tubulin in HCT116 cells^[1].
FLT3-IN-43 (15-30 nM; 24 h) disrupts the cellular microtubule network of HCT116 cells in a concentration-dependent manner, inducing perinuclear contraction of microtubule structures^[1].
FLT3-IN-43 40 min) is a potent, highly selective FLT3 kinase inhibitor with an IC₅₀ of 58.6 nM, showing minimal inhibitory activity against the off-target homologous kinases c-KIT, PDGFRα, and PDGFRβ^[1].
FLT3-IN-43 (15-60 nM; 8 h) effectively inhibits the FLT3 signaling pathway in MOLM-13 cells through concentration-dependent reduction of phosphorylated FLT3 and phosphorylated STAT5 protein levels^[1].
FLT3-IN-43 (5-15 nM; 12-24 h) produces a sequential, time-dependent dual phase arrest phenotype in MOLM-13 cells, with early 12 h G2/M arrest characteristic of tubulin inhibition, transitioning to 24 h G0/G1 arrest characteristic of FLT3 kinase inhibition^[1].
FLT3-IN-43 (5-30 nM; 24 h) induces robust, concentration-dependent apoptosis in MOLM-13 leukemia cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.